Breaking
RAPS Euro Convergence: Top Regulatory Insights - Day 1European Research Revolution: Day 1 HighlightsRAPS Euro Convergence: Key Regulatory Updates - Day 1
🇺🇸 FDA

Multiple Myeloma

Page 1 • 1 item

Access global market intelligence on multiple myeloma drug development, clinical trials, regulatory approvals, and competitive landscapes.

Pfizer's ELREXFIO Shows Significant Progression-Free Survival Improvement in Multiple Myeloma Phase 3 Trial
NewsOncology - Multiple MyelomaApr 29, 2026

Pfizer's ELREXFIO Shows Significant Progression-Free Survival Improvement in Multiple Myeloma Phase 3 Trial

Pfizer's ELREXFIO meets primary endpoint in MagnetisMM-5 Phase 3 trial, showing statistically significant progression-free survival improvement for relapsed multiple myeloma patients.

Dr. Natalie Hughes